Abstract:Background: Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer, therefore causing a death toll comparable to that of melanoma, despite its low propensity to metastasize (2-5%). We recently developed a clinicopathological (CP) model that predicts absolute metastatic risk in cSCC patients. We have recently shown that, in a nationwide Dutch cohort, the model enhances the risk stratification provided by the American Joint Committee on Cancer, eighth edition (AJCC) and the Brigham and Women's Hospital (BWH) staging systems. The current study aims to evaluate the refined risk stratification and designed risk thresholds in an independent, nationwide UK cohort. Methods: In the Dutch cohort, we defined patients at increased risk within the low-risk group (AJCC: T1-T2, BWH: T1-T2a) as those with an estimated risk above 1%; and in the high-risk group (AJCC: T3-T4, BWH: T2b-T3), as those with a risk above 3.5%. Both risk thresholds were evaluated in the nested case-control (NCC) cohort (n=696), sampled from the nationwide UK cohort (n=31981). The CP model was applied to the NCC cohort and results were binarized as CP Low-Risk or CP High-Risk. Weighted metrics were computed to adjust for the difference in proportion of cases and controls between NCC and nationwide cohorts. Results: In the low-risk group as per AJCC (T1-T2) and BWH (T1-T2a), the metastatic risk is respectively 0.93% and 1.07%. Within this group, CP High-Risk patients represent respectively 1.69% and 6.11% of the AJCC and BWH groups and have increased metastatic risk of 7.54% in AJCC and 5.36% in BWH. In the high-risk group as per AJCC (T3-T4) and BWH (T2b-T3), the metastatic risk is respectively 7.79% and 13.80%. Within this group, CP High-Risk patients represent respectively 7.42% and 24.40% of the AJCC and BWH groups. They have an increased metastatic risk of 27.92% in AJCC and 24.07% in BWH. Conclusions: This study validates the designed risk thresholds in an independent nationwide cohort. Differences in performance compared to the Dutch cohort can be explained by the exclusion of patients with multiple missing variables and worse annotation of pathological features in the UK cohort. Additionally, this study confirms that our risk model can enhance cSCC staging systems by a refined risk stratification in both low-risk and high-risk groups. Specifically, the CP High-Risk subgroup within the staging systems' low-risk group might benefit from heightened surveillance and diagnostic screening, such as lymph node ultrasonography. Similarly, the CP High-Risk subgroup within the staging systems' high-risk group could be considered for intensified surveillance and (adjuvant) treatment. In conclusion, adding the CP model to current cSCC staging systems would enable more personalized decisions about follow-up and treatment, while also facilitating the management of healthcare resources. Citation Format: Olivia FM Steijlen, Lara Pozza, Barbara Rentroia-Pacheco, Celeste. J. Eggermont, Domenico Bellomo, Sheril Alex, Jvalini Dwarkasing, Antien L. Mooyaart, Loes M. Hollestein, Marlies Wakkee. Beyond staging systems in cutaneous squamous cell carcinoma: Validation of two thresholds for a model-estimated metastatic risk [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3463.

Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients

A 41-Gene Signature Derived from Breast Cancer Stem Cells As a Predictor of Survival

40-Gene expression profile test predicting metastatic risk in localized, high-risk cutaneous squamous cell carcinoma for peer review

Association of a 40-Gene Expression Profile With Risk of Metastatic Disease Progression of Cutaneous Squamous Cell Carcinoma (cSCC) and Specification of Benefit of Adjuvant Radiation Therapy

Predicting adjuvant radiation therapy benefit in cutaneous squamous cell carcinoma with the 40-gene expression profile

The 31-Gene Expression Profile Test Outperforms AJCC in Stratifying Risk of Recurrence in Patients with Stage I Cutaneous Melanoma

Integrating the melanoma 31-gene expression profile test with clinical and pathologic features can provide personalized precision estimates for sentinel lymph node positivity: an independent performance cohort

The Prognostic Value of the 31-Gene Expression Profile Test in Cutaneous Melanoma: A Systematic Review and Meta-Analysis

Prognostic Gene Signature for Squamous Cell Carcinoma with a Higher Risk for Treatment Failure and Accelerated MEK-ERK Pathway Activity

Inconsistent Associations Between Risk Factor Profiles and Adjuvant Radiation Therapy (ART) Treatment in Patients with Cutaneous Squamous Cell Carcinoma and Utility of the 40-Gene Expression Profile to Refine ART Guidance

Whole Exome and Transcriptome Sequencing of Stage-Matched, Outcome-Differentiated Cutaneous Squamous Cell Carcinoma Identifies Gene Expression Patterns Associated with Metastasis and Poor Outcomes

Comprehensive Genomic Profiling of 443 Patients with Advanced Renal Cell Carcinoma (rcc) to Reveal Clinically Relevant Genomic Alterations and to Aid in Classification of Rare Subtypes.

Prospective Clinical Prognostication of Endometrial Carcinomas Based on Next-Generation Sequencing and Immunohistochemistry-Real-World Implementation and Results at a Tertiary Care Center

Prognostic stratification of endometrial cancers with high microsatellite instability or no specific molecular profile

Transcriptomic analysis of cutaneous squamous cell carcinoma reveals a multi-gene prognostic signature associated with metastasis

Comprehensive genomic profiling (CGP) of squamous cell carcinoma of unknown primary (SCCUP) presenting with inguinal, pelvic, and retroperitoneal (I/P/RP) metastases.

31‐GEP (DecisionDx): a review of clinical utility and performance in a Mayo Clinic cohort

Comprehensive genomic profiling of squamous cell carcinoma of unknown primary presenting with liver metastases.

Abstract 3463: Beyond staging systems in cutaneous squamous cell carcinoma: Validation of two thresholds for a model-estimated metastatic risk

Supplementary Table 3 from Platinum Sensitivity–Related Germline Polymorphism Discovered Via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients

Abstract CT207: Association of gene expression profiles and clinical outcomes in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma treated with pembrolizumab in KEYNOTE-629